Comprehensive Market Analysis Report: Global Visceral Pain Treatment Market (2026-2036)
1. Executive Summary
The global visceral pain treatment market addresses a significant and underserved medical need, targeting pain originating from internal organs. Characterized by complex pathophysiology and diagnostic challenges, this market is poised for transformation through novel, targeted pharmacotherapies. This report provides a refined analysis of market status and forecast from 2026 to 2036, evaluating market size, key innovators, segmentation, and regional dynamics. Driven by a growing understanding of visceral pain pathways and a robust pipeline of first-in-class drugs, the market is expected to experience substantial growth, shifting away from reliance on generic analgesics toward mechanism-specific treatments.
2. Market Overview
-
Market Valuation: The global visceral pain treatment market is projected to grow significantly from 2026 to 2036, reaching a substantial market value by the end of the forecast period, with a promising Compound Annual Growth Rate (CAGR).
-
Base Year: 2025
-
Forecast Period: 2026 - 2036
-
Key Drivers: High prevalence of chronic visceral pain disorders (IBS, endometriosis, interstitial cystitis), significant unmet need and patient dissatisfaction with current therapies, advancement in understanding nociceptive and neuropathic visceral pathways, and a strong pipeline of targeted therapies.
-
Primary Challenges: Diagnostic complexity and patient heterogeneity, potential placebo response in clinical trials, regulatory hurdles for novel pain mechanisms, and market penetration against entrenched, low-cost generic analgesics.
3. Key Market Players
The landscape includes pharmaceutical companies and biotechs developing novel targeted therapies.
-
Leading Innovators & Pipeline Companies:
-
Astellas Pharma Inc. (Fezolinetant for menopausal symptoms, pain-related research)
-
Pfizer Inc. (Broad neuroscience portfolio, involvement in pain research)
-
Grünenthal GmbH (Specialist in pain, pipeline includes visceral pain targets)
-
Addex Therapeutics Ltd (Allosteric modulators for neurological disorders)
-
Vertex Pharmaceuticals Incorporated (Nav1.8 inhibitors for pain, including visceral)
-
Ironwood Pharmaceuticals, Inc. (Linaclotide for IBS-C, expertise in GI disorders)
-
Ardelyx, Inc. (Tenapanor for IBS-C, targeting visceral sensation)
-
Allakos Inc. (Targeting mast cells and neuro-immune interactions)
-
Vanda Pharmaceuticals Inc. (Tradipitant for gastroparesis-associated symptoms)
-
-
Other Notable Entities: Chromocell Corporation, GIcare Pharma Inc., Medestea Research & Production S.p.A., Neurim Pharmaceuticals Ltd., Cara Therapeutics, Inc. (KOR agonist for uremic pruritus and pain), Trevena, Inc. (Biased opioid receptor ligands).
4. Market Segmentation Analysis
4.1 By Drug Class & Mechanism of Action
-
Peripheral Visceral Analgesics (Novel Targets): Fastest-growing segment.
-
*Sodium Channel Blockers (e.g., Nav1.8 inhibitors like VX-548)*
-
*P2X3 Receptor Antagonists (e.g., BLU-5937 for chronic cough, pain potential)*
-
Transient Receptor Potential (TRP) Channel Modulators (e.g., TRPV1, TRPA1)
-
-
Centrally-Acting Agents:
-
Kappa Opioid Receptor (KOR) Agonists (e.g., difelikefalin, CR845) - Minimizing CNS side effects.
-
Gabapentinoids (Pregabalin, Gabapentin) - Used off-label; established but generic.
-
-
Disease-Modifying Agents: Targeting underlying inflammation or hypersensitivity (e.g., mast cell stabilizers, biologics for IBD-related pain).
-
Traditional Analgesics: Includes opioids (limited use due to side effects), NSAIDs, antispasmodics (e.g., dicyclomine, hyoscine). Mature, generic segment.
4.2 By Indication
-
Gastrointestinal Disorders: Largest segment (Irritable Bowel Syndrome, Inflammatory Bowel Disease pain, functional dyspepsia).
-
Urological Disorders: Interstitial cystitis/Bladder Pain Syndrome, chronic prostatitis.
-
Gynecological Disorders: Endometriosis-associated pain, chronic pelvic pain.
-
Pancreatic & Other Visceral Pain: Chronic pancreatitis, pain from solid organ cancers.
4.3 By Application/Setting
-
Out-patient: Dominant segment. Includes primary care, gastroenterology, urology, gynecology, and pain specialty clinics for chronic management.
-
In-patient: For acute exacerbations, post-operative visceral pain, or severe disease flare-ups requiring hospitalization.
5. Regional Analysis
-
North America: Leading market share due to high disease awareness, advanced diagnostic capabilities, favorable reimbursement for novel therapies, and concentration of biotech R&D.
-
Europe: Strong second market with robust clinical research and rising focus on functional GI disorders. Growth is tied to centralized EMA approvals and national reimbursement decisions.
-
Asia-Pacific: Projected fastest-growing region. Driven by large patient pools, increasing healthcare spending, growing recognition of visceral pain syndromes, and expansion of key players.
-
Latin America, Middle East & Africa: Emerging markets where growth is contingent on improving diagnostic rates and gradual market entry of novel therapies after launch in major regions.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants: Moderate. High R&D costs and complex clinical trials are barriers, but the significant unmet need and premium pricing potential attract specialized biotechs.
-
Bargaining Power of Suppliers: Low for standard chemicals, but moderate for specialized CROs with expertise in visceral pain clinical endpoints (e.g., patient-reported outcomes).
-
Bargaining Power of Buyers: High. Payers (insurance, government) negotiate aggressively, especially for chronic conditions requiring long-term therapy. Patients have limited direct power.
-
Threat of Substitutes: Moderate. Includes non-pharmacological therapies (cognitive behavioral therapy, diet, neuromodulation), generic drugs, and off-label use of existing medications.
-
Industry Rivalry: Increasing from moderate to high. Competition is intensifying as multiple novel mechanisms enter mid- and late-stage trials, striving for differentiation in efficacy and safety.
7. SWOT Analysis
-
Strengths: Large and growing patient population, high unmet need creating receptive market, potential for premium pricing for first-in-class drugs, strong scientific foundation.
-
Weaknesses: High clinical trial failure risk due to subjective endpoints and placebo response, patient heterogeneity complicates trial design, need for specialized diagnostics.
-
Opportunities: Development of companion diagnostics for patient stratification, expansion into new visceral pain indications, combination therapies, digital therapeutics for adjunctive management.
-
Threats: Stringent regulatory requirements for proving analgesic efficacy, payer resistance to high-cost chronic therapies, strong generic competition in established drug classes.
8. Trend Analysis
-
Shift from Centrally- to Peripherally-Acting Drugs: Strong focus on developing analgesics that target visceral sensory nerves specifically, minimizing CNS-related side effects (sedation, abuse potential).
-
Precision Medicine Approach: Growing research into biomarkers and patient phenotypes (e.g., IBS subtypes) to tailor treatment and improve clinical trial success.
-
Integration of Non-Pharmacological Data: Use of digital health tools (apps, wearables) to capture real-world pain and quality-of-life data for clinical trials and market differentiation.
-
Repurposing & Reformulation: Exploring existing drugs with novel mechanisms for visceral pain (e.g., P2X3 antagonists from cough).
9. Market Drivers & Challenges
-
Drivers:
-
Rising prevalence of chronic visceral pain disorders linked to lifestyle and diagnostic improvements.
-
Increased recognition of visceral pain as a distinct neurological entity.
-
Substantial venture capital and pharmaceutical investment in novel pain targets.
-
Strong patient advocacy driving research and development priorities.
-
-
Challenges:
-
Difficulty in objectively measuring pain and demonstrating statistical superiority over placebo.
-
Navigating heterogeneous payer landscapes and formularies for chronic conditions.
-
Educating a broad base of physicians across specialties on new treatment paradigms.
-
Demonstrating cost-effectiveness versus cheap, generic alternatives.
-
10. Value Chain Analysis
-
Basic Research & Target Identification: Academic and biotech research into visceral nociception, ion channels, and neuro-immune interactions.
-
Drug Discovery & Preclinical Development: High-throughput screening and animal model development specific to visceral pain.
-
Clinical Development: Complex trials using validated patient-reported outcome measures (PROs) and often requiring specialized recruitment networks.
-
Regulatory & Market Access: Engaging with regulators on novel endpoints and demonstrating meaningful clinical benefit. Early health economic outcomes research for payers.
-
Manufacturing: Standard pharmaceutical manufacturing for small molecules; potential for more complex processes for biologics.
-
Commercialization & Marketing: Targeted detailing to gastroenterologists, urologists, gynecologists, and pain specialists. Direct-to-patient education campaigns.
-
Post-Marketing Surveillance & Outcomes Research: Critical for understanding long-term use and real-world effectiveness in diverse populations.
11. Strategic Recommendations for Stakeholders
-
For Pharmaceutical Companies: Invest in biomarker research to enable targeted clinical trials and personalized medicine. Develop strong health economics and outcomes research (HEOR) packages early. Consider combination therapy strategies with existing standard-of-care.
-
For Investors: Focus on companies with validated novel targets, strong translational science, and experienced management teams in neurology/GI. Differentiated clinical trial designs are a key indicator of potential success.
-
For Healthcare Providers: Stay informed on emerging mechanism-based treatments to move beyond empirical therapy. Participate in registries and clinical trials to advance the field. Adopt a multidisciplinary approach to patient management.
-
For Payers & Policymakers: Develop nuanced reimbursement policies that recognize the high unmet need and value of effective targeted therapies, potentially with outcomes-based agreements. Support research into diagnostic standardization.
-
For Patients & Advocacy Groups: Participate in clinical trials to accelerate drug development. Collaborate with researchers to ensure patient-centric endpoints are used. Advocate for broader insurance coverage for multidisciplinary care.
Table of Contents
Global Visceral Pain Treatment Market Research Report 2026
1 Industry Overview of Visceral Pain Treatment
1.1 Definition and Specifications of Visceral Pain Treatment
1.1.1 Definition of Visceral Pain Treatment
1.1.2 Specifications of Visceral Pain Treatment
1.2 Classification of Visceral Pain Treatment
1.2.1 HS-665
1.2.2 CC-8464
1.2.3 BLU-5937
1.2.4 APD-371
1.2.5 Others
1.3 Applications of Visceral Pain Treatment
1.3.1 In-patient
1.3.2 Out-patient
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Visceral Pain Treatment
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Visceral Pain Treatment
2.3 Manufacturing Process Analysis of Visceral Pain Treatment
2.4 Industry Chain Structure of Visceral Pain Treatment
3 Technical Data and Manufacturing Plants Analysis of Visceral Pain Treatment
3.1 Capacity and Commercial Production Date of Global Visceral Pain Treatment Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Visceral Pain Treatment Major Manufacturers
3.3 R&D Status and Technology Source of Global Visceral Pain Treatment Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Visceral Pain Treatment Major Manufacturers
4 Global Visceral Pain Treatment Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Visceral Pain Treatment Capacity and Growth Rate Analysis
4.2.2 Visceral Pain Treatment Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Visceral Pain Treatment Sales and Growth Rate Analysis
4.3.2 Visceral Pain Treatment Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Visceral Pain Treatment Sales Price
4.4.2 Visceral Pain Treatment Sales Price Analysis (Company Segment)
5 Visceral Pain Treatment Regional Market Analysis
5.1 North America Visceral Pain Treatment Market Analysis
5.1.1 North America Visceral Pain Treatment Market Overview
5.1.2 North America E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Visceral Pain Treatment Sales Price Analysis
5.1.4 North America Visceral Pain Treatment Market Share Analysis
5.2 Europe Visceral Pain Treatment Market Analysis
5.2.1 Europe Visceral Pain Treatment Market Overview
5.2.2 Europe E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Visceral Pain Treatment Sales Price Analysis
5.2.4 Europe Visceral Pain Treatment Market Share Analysis
5.3 China Visceral Pain Treatment Market Analysis
5.3.1 China Visceral Pain Treatment Market Overview
5.3.2 China E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Visceral Pain Treatment Sales Price Analysis
5.3.4 China Visceral Pain Treatment Market Share Analysis
5.4 Japan Visceral Pain Treatment Market Analysis
5.4.1 Japan Visceral Pain Treatment Market Overview
5.4.2 Japan E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Visceral Pain Treatment Sales Price Analysis
5.4.4 Japan Visceral Pain Treatment Market Share Analysis
5.5 Southeast Asia Visceral Pain Treatment Market Analysis
5.5.1 Southeast Asia Visceral Pain Treatment Market Overview
5.5.2 Southeast Asia E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Visceral Pain Treatment Sales Price Analysis
5.5.4 Southeast Asia Visceral Pain Treatment Market Share Analysis
5.6 India Visceral Pain Treatment Market Analysis
5.6.1 India Visceral Pain Treatment Market Overview
5.6.2 India E Visceral Pain Treatment Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Visceral Pain Treatment Sales Price Analysis
5.6.4 India Visceral Pain Treatment Market Share Analysis
6 Global E Visceral Pain Treatment Segment Market Analysis (by Type)
6.1 Global E Visceral Pain Treatment Sales by Type
6.2 Different Types of Visceral Pain Treatment Product Interview Price Analysis
6.3 Different Types of Visceral Pain Treatment Product Driving Factors Analysis
6.3.1 HS-665 Growth Driving Factor Analysis
6.3.2 CC-8464 Growth Driving Factor Analysis
6.3.3 BLU-5937 Growth Driving Factor Analysis
6.3.4 APD-371 Growth Driving Factor Analysis
6.3.5 Others Growth Driving Factor Analysis
7 Global E Visceral Pain Treatment Segment Market Analysis (by Application)
7.1 Global E Visceral Pain Treatment Consumption by Application
7.2 Different Application of Visceral Pain Treatment Product Interview Price Analysis
7.3 Different Application of Visceral Pain Treatment Product Driving Factors Analysis
7.3.1 In-patient of Visceral Pain Treatment Growth Driving Factor Analysis
7.3.2 Out-patient of Visceral Pain Treatment Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Visceral Pain Treatment
8.1 Addex Therapeutics Ltd
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Addex Therapeutics Ltd Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Addex Therapeutics Ltd Visceral Pain Treatment Business Region Distribution Analysis
8.2 Astellas Pharma Inc.
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Astellas Pharma Inc. Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Astellas Pharma Inc. Visceral Pain Treatment Business Region Distribution Analysis
8.3 Chromocell Corporation
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Chromocell Corporation Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Chromocell Corporation Visceral Pain Treatment Business Region Distribution Analysis
8.4 GIcare Pharma Inc
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 GIcare Pharma Inc Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 GIcare Pharma Inc Visceral Pain Treatment Business Region Distribution Analysis
8.5 Grunenthal GmbH
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Grunenthal GmbH Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Grunenthal GmbH Visceral Pain Treatment Business Region Distribution Analysis
8.6 Medestea Research & Production S.p.A.
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Medestea Research & Production S.p.A. Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Medestea Research & Production S.p.A. Visceral Pain Treatment Business Region Distribution Analysis
8.7 Neurim Pharmaceuticals Ltd
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Neurim Pharmaceuticals Ltd Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Neurim Pharmaceuticals Ltd Visceral Pain Treatment Business Region Distribution Analysis
8.8 Pfizer Inc.
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Pfizer Inc. Visceral Pain Treatment Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Pfizer Inc. Visceral Pain Treatment Business Region Distribution Analysis
9 Development Trend of Analysis of Visceral Pain Treatment Market
9.1 Global Visceral Pain Treatment Market Trend Analysis
9.1.1 Global 2018-2025 Visceral Pain Treatment Market Size (Volume and Value) Forecast
9.1.2 Global 2018-2025 Visceral Pain Treatment Sales Price Forecast
9.2 Visceral Pain Treatment Regional Market Trend
9.2.1 North America 2018-2025 Visceral Pain Treatment Consumption Forecast
9.2.2 Europe 2018-2025 Visceral Pain Treatment Consumption Forecast
9.2.3 China 2018-2025 Visceral Pain Treatment Consumption Forecast
9.2.4 Japan 2018-2025 Visceral Pain Treatment Consumption Forecast
9.2.5 Southeast Asia 2018-2025 Visceral Pain Treatment Consumption Forecast
9.2.6 India 2018-2025 Visceral Pain Treatment Consumption Forecast
9.3 Visceral Pain Treatment Market Trend (Product Type)
9.4 Visceral Pain Treatment Market Trend (Application)
10 Visceral Pain Treatment Marketing Type Analysis
10.1 Visceral Pain Treatment Regional Marketing Type Analysis
10.2 Visceral Pain Treatment International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Visceral Pain Treatment by Region
10.4 Visceral Pain Treatment Supply Chain Analysis
11 Consumers Analysis of Visceral Pain Treatment
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Visceral Pain Treatment Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Visceral Pain Treatment
Table Product Specifications of Visceral Pain Treatment
Table Classification of Visceral Pain Treatment
Figure Global Production Market Share of Visceral Pain Treatment by Type in
Figure HS-665 Picture
Table Major Manufacturers of HS-665
Figure CC-8464 Picture
Table Major Manufacturers of CC-8464
Figure BLU-5937 Picture
Table Major Manufacturers of BLU-5937
Figure APD-371 Picture
Table Major Manufacturers of APD-371
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Visceral Pain Treatment
Figure Global Consumption Volume Market Share of Visceral Pain Treatment by Application in
Figure In-patient Examples
Table Major Consumers in In-patient
Figure Out-patient Examples
Table Major Consumers in Out-patient
Figure Market Share of Visceral Pain Treatment by Regions
Figure North America Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Figure Europe Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Figure China Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Figure Japan Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Figure Southeast Asia Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Figure India Visceral Pain Treatment Market Size (Million USD) (2013-2025)
Table Visceral Pain Treatment Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Visceral Pain Treatment in
Figure Manufacturing Process Analysis of Visceral Pain Treatment
Figure Industry Chain Structure of Visceral Pain Treatment
Table Capacity and Commercial Production Date of Global Visceral Pain Treatment Major Manufacturers
Table Manufacturing Plants Distribution of Global Visceral Pain Treatment Major Manufacturers
Table R&D Status and Technology Source of Global Visceral Pain Treatment Major Manufacturers
Table Raw Materials Sources Analysis of Global Visceral Pain Treatment Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Visceral Pain Treatment E
Figure Global E Visceral Pain Treatment Market Size (Volume) and Growth Rate
Figure Global E Visceral Pain Treatment Market Size (Value) and Growth Rate
Table E Global Visceral Pain Treatment Capacity and Growth Rate
Table Global Visceral Pain Treatment Capacity (K Pcs) List (Company Segment)
Table E Global Visceral Pain Treatment Sales (K Pcs) and Growth Rate
Table Global Visceral Pain Treatment Sales (K Pcs) List (Company Segment)
Table E Global Visceral Pain Treatment Sales Price (USD/Pcs)
Table Global Visceral Pain Treatment Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure North America E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure North America Visceral Pain Treatment Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure Europe E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure Europe Visceral Pain Treatment Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure China E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure China Visceral Pain Treatment Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure Japan E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure Japan Visceral Pain Treatment Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure Southeast Asia E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure Southeast Asia Visceral Pain Treatment Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Visceral Pain Treatment E
Figure India E Visceral Pain Treatment Sales Price (USD/Pcs)
Figure India Visceral Pain Treatment Sales Market Share
Table Global E Visceral Pain Treatment Sales (K Pcs) by Type
Table Different Types Visceral Pain Treatment Product Interview Price
Table Global E Visceral Pain Treatment Sales (K Pcs) by Application
Table Different Application Visceral Pain Treatment Product Interview Price
Table Addex Therapeutics Ltd Information List
Table Product Overview
Table Addex Therapeutics Ltd Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Addex Therapeutics Ltd Visceral Pain Treatment Business Region Distribution
Table Astellas Pharma Inc. Information List
Table Product Overview
Table Astellas Pharma Inc. Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Astellas Pharma Inc. Visceral Pain Treatment Business Region Distribution
Table Chromocell Corporation Information List
Table Product Overview
Table Chromocell Corporation Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Chromocell Corporation Visceral Pain Treatment Business Region Distribution
Table GIcare Pharma Inc Information List
Table Product Overview
Table GIcare Pharma Inc Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure GIcare Pharma Inc Visceral Pain Treatment Business Region Distribution
Table Grunenthal GmbH Information List
Table Product Overview
Table Grunenthal GmbH Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Grunenthal GmbH Visceral Pain Treatment Business Region Distribution
Table Medestea Research & Production S.p.A. Information List
Table Product Overview
Table Medestea Research & Production S.p.A. Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Medestea Research & Production S.p.A. Visceral Pain Treatment Business Region Distribution
Table Neurim Pharmaceuticals Ltd Information List
Table Product Overview
Table Neurim Pharmaceuticals Ltd Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Neurim Pharmaceuticals Ltd Visceral Pain Treatment Business Region Distribution
Table Pfizer Inc. Information List
Table Product Overview
Table Pfizer Inc. Visceral Pain Treatment Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Pfizer Inc. Visceral Pain Treatment Business Region Distribution
Figure Global 2018-2025 Visceral Pain Treatment Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2018-2025 Visceral Pain Treatment Market Size (Million USD) and Growth Rate Forecast
Figure Global 2018-2025 Visceral Pain Treatment Sales Price (USD/Pcs) Forecast
Figure North America 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2018-2025 Visceral Pain Treatment Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Visceral Pain Treatment by Type 2018-2025
Table Global Consumption Volume (K Pcs) of Visceral Pain Treatment by Application 2018-2025
Table Traders or Distributors with Contact Information of Visceral Pain Treatment by Region
Key Market Players
The landscape includes pharmaceutical companies and biotechs developing novel targeted therapies.
-
Leading Innovators & Pipeline Companies:
-
Astellas Pharma Inc. (Fezolinetant for menopausal symptoms, pain-related research)
-
Pfizer Inc. (Broad neuroscience portfolio, involvement in pain research)
-
Grünenthal GmbH (Specialist in pain, pipeline includes visceral pain targets)
-
Addex Therapeutics Ltd (Allosteric modulators for neurological disorders)
-
Vertex Pharmaceuticals Incorporated (Nav1.8 inhibitors for pain, including visceral)
-
Ironwood Pharmaceuticals, Inc. (Linaclotide for IBS-C, expertise in GI disorders)
-
Ardelyx, Inc. (Tenapanor for IBS-C, targeting visceral sensation)
-
Allakos Inc. (Targeting mast cells and neuro-immune interactions)
-
Vanda Pharmaceuticals Inc. (Tradipitant for gastroparesis-associated symptoms)
-
-
Other Notable Entities: Chromocell Corporation, GIcare Pharma Inc., Medestea Research & Production S.p.A., Neurim Pharmaceuticals Ltd., Cara Therapeutics, Inc. (KOR agonist for uremic pruritus and pain), Trevena, Inc. (Biased opioid receptor ligands).
4. Market Segmentation Analysis
4.1 By Drug Class & Mechanism of Action
-
Peripheral Visceral Analgesics (Novel Targets): Fastest-growing segment.
-
*Sodium Channel Blockers (e.g., Nav1.8 inhibitors like VX-548)*
-
*P2X3 Receptor Antagonists (e.g., BLU-5937 for chronic cough, pain potential)*
-
Transient Receptor Potential (TRP) Channel Modulators (e.g., TRPV1, TRPA1)
-
-
Centrally-Acting Agents:
-
Kappa Opioid Receptor (KOR) Agonists (e.g., difelikefalin, CR845) - Minimizing CNS side effects.
-
Gabapentinoids (Pregabalin, Gabapentin) - Used off-label; established but generic.
-
-
Disease-Modifying Agents: Targeting underlying inflammation or hypersensitivity (e.g., mast cell stabilizers, biologics for IBD-related pain).
-
Traditional Analgesics: Includes opioids (limited use due to side effects), NSAIDs, antispasmodics (e.g., dicyclomine, hyoscine). Mature, generic segment.
4.2 By Indication
-
Gastrointestinal Disorders: Largest segment (Irritable Bowel Syndrome, Inflammatory Bowel Disease pain, functional dyspepsia).
-
Urological Disorders: Interstitial cystitis/Bladder Pain Syndrome, chronic prostatitis.
-
Gynecological Disorders: Endometriosis-associated pain, chronic pelvic pain.
-
Pancreatic & Other Visceral Pain: Chronic pancreatitis, pain from solid organ cancers.
4.3 By Application/Setting
-
Out-patient: Dominant segment. Includes primary care, gastroenterology, urology, gynecology, and pain specialty clinics for chronic management.
-
In-patient: For acute exacerbations, post-operative visceral pain, or severe disease flare-ups requiring hospitalization.
